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INTRODUCTION
The pathogenesis of adult periodontitis involves a complex interaction
between bacterial factors and the host immune response. Although a great
deal has been learned about this interaction, a poor understanding of the
susceptibility of individuals to periodontal disease processes still exists.
Clinical research has attempted to correlate periodontal attachment loss with
specific alterations in gingival crevicular fluid (8,43,44), subgingival bacterial
flora (12) or histological surveys (45,48,60). This approach has generated
useful information, however, results have generally not provided satisfactory
methods for predicting disease activity or patient susceptibility. Hundreds of
bacterial species have been identified in subgingival plaque (39). The extreme
complexity of this subgingival ecology prevents the identification of one or
more bacteria as the causative factor in periodontitis. Furthermore, the
importance of bacterial products such as collagenase, leukotoxins, and
lipopolysaccharide (LPS) are hard to assess in situ. The examination of
crevicular fluid for levels of soluble immune mediators such as
prostaglandins, interleukins, complement fragments, and/or cellular
enzymes, fails to identify the role of these mediators in promoting pathogenic
processes within established periodontitis lesions. Furthermore, bacteria
present in the crevice or pocket release a number of proteolytic enzymes
which may alter those mediators being examined (68). Humoral immune
responses to suspected periodontal pathogens have established the existence
of a systemic immune response to oral microorganisms associated with
periodontitis. However, these responses have not provided information
useful in predicting periodontal breakdown or patient susceptibility to
periodontitis.
With the development of counterflow centrifugation it is now possible
to rapidly isolate, in high purity, monocytes from fresh peripheral blood. By
combining this cell isolation technique with in vitro cell culture methods, a
different approach to the study of immune function and regulation in
periodontitis is possible. In addition, this approach is conveniently applied to
assessment of monocyte responses and their relationship to periodontitis in
dental patients. Therefore, these methods were employed in the investigation
of immune function as described below.
This thesis proposes to study whether cells from human subjects
possess an inherent ability to respond to LPS which can be correlated with the
degree of periodontal destruction within the same individuals. According to
this model, LPS released from the subgingival flora activates cells of the
monocyte and lymphocyte lineages to various levels of immune and
inflammatory function. Alterations in this process could occur through the
innate variability of LPS-responsiveness. One aspect of LPS-induced immune
and inflammatory responses involves the release of soluble mediators, such
as, IL-1 and PGE2 from monocytes. Products such as these, play an important
role in the regulation of inflammatory and immune processes. Therefore,
.alterations in the levels of these, and other regulating substances could have
profound effects on the character of the local immune and inflammatory
responses. Alterations in the LPS-stimulated release of these substances can
also occur through the activities of natural immune regulatory substances
such as gamma interferon (IFN-/). Prior to conducting a clinical investigation
of this hypothesis, it was necessary to partially characterize LPS and IFN-,
effects on monocyte release of PGE2 and IL-1. Therefore, the three primary
goals of this research project were to 1) characterize and compare the relative
potencies of LPS preparations from various suspected periodontal pathogens
in the stimulation of PGE2 and/or IL-1 release 2) analyze the effects of IFN-y
on LPS stimulated responses ,and lastly, using this information, 3) conduct a
pilot clinical study of the LPS-responsiveness of patients and its correlation to
periodontitis-susceptibility.
An abundance of evidence suggests the importance of bacterial
lipopolysaccharide (LPS) in the pathogenesis of periodontitis. LPS is a
constituent of the cell wall of gram negative bacteria and is released upon cell
lysis or through a process similar to yeast "budding off" (9). Because gram
negative bacteria predominate within the sulcus and periodontal pocket in
periodontitis (32), LPS may participate, to a major degree, in periodontal
pathogenic mechanisms. Research has shown that 3H-LPS can penetrate
sulcular epithelium (59), thus demonstrating the ability of LPS to penetrate
clinically healthy, gingival soft tissues. In addition, application of LPS to tooth
surfaces is associated with vascular leakage in the adjacent connective tissue
(51). The positive correlation between levels of LPS in the gingival fluid with
clinical (60) and histological (61) signs of periodontal inflammation gives
additional support for the importance of LPS in periodontitis.
Research conducted with C3H murine strains has determined that the
.ability of murine cells to respond to LPS is genetically determined (66) and
that the gene locus is on chromosome 4 (75). The possibility that LPS
responses may be genetically determined in humans raises important
considerations with respect to diseases, such as periodontitis, where host cells
are exposed to bacterial LPS. LPS-induced pathologic changes within the
periodontium would likely involve both lymphocytes and monocytes.
Various findings support the role of cells from the monocyte-
macrophage lineage in periodontal pathogenesis. They are found in elevated
numbers in diseased periodontal connective tissues (58). More importantly,
monocytes release many substances capable of modulating the function of
surrounding cells and connective tissue metabolism. Specifically, monocytes
exposed to LPS, release PGE2 (29) and IL-1 (2). The importance of PGE2 in
periodontitis is suggested by the increased amounts found in periodontally
diseased tissues (18,34,38) and crevicular fluid (44). The proinflammatory,
immunosuppresive, and bone resorbing activities of PGE2 are undoubtedly
important in the regulation of periodontal destruction. IL-1 also possesses
bone resorbing activity (19) and has been found in crevicular fluid (8).
However, the effects of IL-1 on other cells are potentially more important
with respect to periodontal destruction. IL-1 stimulates the release of PGE2
(11) and collagenase (50) from fibroblasts. In this manner, LPS stimulation
results in PGE2 and collagenase release directly from monocytes and indirectly
from fibroblasts, via IL-1. Recently, the release of IL-1 and PGE2 have been
shown to be interrelated (28). It has been demonstrated that I1-1 alone,
stimulated PGE2 release, whereas, exogenous PGE2 inhibited IL-1 release.
Furthermore, inhibition of PGE2 release by indomethicin resulted in elevated
IL-1 release. Another important function of IL-1 pertains to its role as a
cofactor in the activation of T lymphocytes. Treatment of T cells with IL-1
results in expression of interleukin-2 (IL-2) receptors (25). This allows T cell
activation by IL-2, resulting in blastogenesis and the release of IFN-/(30).
Recent evidence suggests that in certain stages of chronic periodontitis,
T lymphocyte numbers predominate over B cells within periodontal
connective tissues (45,60). Interestingly, it has also been demonstrated that
LPS-treated monocytes can stimulate the release of IFN-/from T lymphocytes
(30). This finding has important implications for the study of LPS-monocyte
interactions in periodontal pathogenesis. IFN-/ effects various aspects of
monocyte function, including elevated expression of Ia antigen (27) and Fc
receptors (20,49), resulting in increased efficiency of phagocytosis and antigen
presentation. Furthermore, LPS stimulated monocyte responses such as
tumoricidal activity and IL-1 release are increased with IFN- treatment (2,47).
Because T cells and monocytes are both elevated within inflamed periodontal
tissues, examination of the effect of IFN- on LPS-stimulated monocyte
responses was also include in this work.
CHAPTER 1
Lipopolysaccharide stimulated PGE2 release from human monocytes:
comparison of lipopolysaccharides prepared from suspected periodontal
pathogens.
ABSTRACT
Lipopolysaccharides (LPS) prepared from the suspected periodontal
pathogens Actinobacillus actinomycetemcomitans, Bacteroides gingivalis, B.
intermedius and Wolinella recta were compared to Salmonella
typhimurium LPS, for their capacity to stimulate PGE2 release from human
monocytes. Counterflow isolated monocytes were cultured with control
medium or media containing 10 ug/ml LPS. Media were then exchanged
every 24 hours for a total of 72 hours. Salmonella and Wolinella LPS
preparations demonstrated 7-fold greater PGE2 release than B. gingivalis and
5-fold greater than A. a. and B. intermedius. PGE2 release was found to
decrease over time with all LPS preparations except Wolinella. The potency of
the LPS preparations is tentatively ranked as follows" Wolinella >
Salmonella > A. a. > B. intermedius > B. gingivalis. These findings
demonstrate that LPS preparations from suspected periodontal pathogens are
capable of stimulating PGE2 release from human monocytes. The high
potency and prolonged stimulation of PGE2 release with Wolinella LPS
suggests unusual toxic properties which may exert a greater influence in the
pathogenesis of destructive periodontal diseases.
INTRODUCTION
According to current evidence, the progression of adult periodontitis
may be associated with the presence of certain gram negative bacteria,
including Wolinella recta, Actinobacillus actinomycetemcomitans (A. a.), and
Bacteroides species (12). A. a. has also been associated with the progression of
localized juvenile periodontitis (63). Although an association with clinical
attachment loss may implicate these organisms in the pathogenesis of
periodontal diseases, the specific mechanisms by which they promote peri-
odontal destruction remain to be established. Each of the previously
described gram negative species possess lipopolysaccharide (LPS) as a cell wall
constituent. However, numerous structural and functional differences have
been reported for lipopolysaccharides isolated from these suspected
periodontal pathogens (4,24,26,36,41,69). Although the release of LPS from
organisms within the subgingival plaque has not been related to periodontal
destructive processes, LPS levels in gingival crevicular fluid have been pos-
itively correlated with clinical and histologic signs of gingival inflammation
(61,62) In addition, isotopically-labelled LPS can penetrate intact sulcular
epithelium (59) and the topical application of LPS to tooth surfaces leads to
increased vascular permeability within the adjacent gingiva (51) Other
pathological responses elicited by LPS include abscess formation, osteoclast-
mediated bone resorption, pyrogenicity, and initiation of the localized
Schwartzman reaction (reviewed in 16). These responses have previously
been used to compare the relative potencies of LPS preparations, however,
the capacity to elicit these pathologic responses may not correlate with
periodontal tissue destruction. Furthermore, LPS potencies within these bio-
logical assay systems may not be relevant to the pathogenesis of periodontal
diseases. The purpose of the present study was to assess the relative potencies
of these LPS preparations within the context of a specific cellular response
considered important in the pathogenesis of periodontitis.
Elevated release of prostaglandin E2 (PGE2) is a prominent response of
monocytes when exposed to LPS (55) In addition, release of PGE2 has been
proposed as a mechanism involved in the pathogenesis of periodontitis
(18,38). The ability of PGE2 to modulate inflammatory and immune reactions,
as well as bone resorption support this idea (65). Furthermore, PGE2 (18,34,38)
and mononuclear phagocytes (58) are increased in the connective tissue of
adult periodontitis lesions. Although an impressive release of PGE2 can be
demonstrated following treatment of monocytes with LPS from Salmonella
typhimurium there is little information available concerning PGE2 release
elicited by LPS preparations isolated from suspected periodontal pathogens.
In the present study, we examined the capacity of LPS preparations isolated
from Bacteroides gingivalis, B. intermedius, Actinobacillus
actinomycetemcomitans, and Wolinella recta to elicit elevated PGE2 release
from human monocytes. LPS from Salmonella typhimurium was used as a
reference for comparative purposes, since considerable data exists concerning
its structure and biologic activities.
METHODS AND MATERIALS
Cell Separation" Monocytes were separated from citrated whole
venous blood of random human donors by ficoll-Hypaque sedimentation
(400 x g x 35 min.)at 10oc. The mononuclear leukocyte rich fractions were
collected, diluted, and washed two times in Ca++ and Mg++ free, phosphate
buffered saline (PBS) (125 x g x 15 min.) at 10oc. The cells were then counted
electronically (Coulter Electronics) and monocyte enrichment achieved by
counterflow centrifugation (Beckman Instruments). Autologous plasma (1%)
was added and monocytes sedimented (125 x g x 15 min.) and resuspended in
MCDB 104 medium (37) supplemented with 1% defined heat inactivated fetal
calf serum (Hyclone), 100 U/ml penicillin and 100 mcg/ml streptomycin.
Cells were counted and plated in plastic (Falcon Plastics) 16mm wells (1 x 106
cells/ml per well). At 2 hours the cells were washed two times in medium to
remove any non-adherent cells. Cultures were incubated at 37oc in an H20
saturated 5% CO2 atmosphere. Cell viability was routinely confirmed by
trypan blue exclusion. Treatments consisted of the following: LPS (10 ug/ml)
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or control medium. Media were exchanged at 24, 48, and 72 hours and the
supernatants assayed for PGE2 content.
LPS Preparations" LPS was obtained from the following bacterial
strains" Salmonella typhimurium (Difco Laboratories), Bacteroides gingivalis,
Bacteroides intermedius, Actinobacillus actinomycetemcomitans, and
Wolinella recta. Periodontal microorganisms were isolated from periodontal
lesions of dental patients. Bacteria were identified, purified and grown to late
logarithmic phase in basal broth. Cells were then pelleted, lyophilized, and
LPS extracted by the hot phenol-water method of Westphal and Jann (76).
Wolinella recta LPS was prepared by the method of Darveau and Hancock
(10). Protein content of the LPS preparations was assayed by the method of
Lowry (35) using fraction V bovine albumin (Pentax) as protein standard.
Assay for PGE2" Levels of PGE2 in the culture supernatants were
assayed by radioimmunoassay using absorption to dextran-coated charcoal.
Anti-PGE2 antibody and 3H-PGE2 were purchased from Seragen and New
England Nuclear, respectively. The anti-PGE2 antibody demonstrates 100%
cross-reactivity with PGE, however, other investigations in this laboratory
have demonstrated that the E series prostaglandin released from human
counterflow isolated monocytes consists of >97% PGE2 when assayed by gas
chromatography-mass spectrometry (manuscript submitted). The PGE2 levels
in culture supernatants were extrapolated from PGE2 standard binding
utilizing logit-log transformation.
Data Analysis" Data are represented in Tables 1 and 2 as ng/ml of PGE2
in culture supernatants. Differences between treatment means were tested by
the independent-samples paired t-test. Data presented are from 6 experiments
except where indicated.
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RESULTS
Salmonella, B. intermedius, and B. gingivalis LPS preparations were
found to contain 5.1%, 6.9%, 11.9% protein, respectively, as measured by
Lowry assay. Protein was undetectable in Wolinella and A.a. LPS
preparations.
Table 1 demonstrates the amounts of PGE2 released during three
consecutive 24 hour intervals from monocytes treated with Salmonella, A. a.,
B. intermedius and B. gingivalis LPS preparations. Salmonella was the
most potent LPS tested over all three time intervals resulting in
approximately two-fold more PGE2 release than B. intermedius and A. acti-
nomycetemcomitans and seven-fold more than B. gingivalis. Lipopolysac-
charides from B. intermedius and A. a. demonstrated similar abilities to
stimulate PGE2 release during the 0-24 hour interval, however, A. a.
stimulated release was significantly greater than B. intermedius for the 24-48
and 48-72 hour intervals. A.a. and B. intermedius LPS stimulated PGE2
release were approximately three to four times the release found with B.
gingivalis which only differed significantly from controls during the initial
24 hour interval. Of interest was the finding that the differences found with
B. intermedius and gingivalis were not significantly different. It can also be
noticed that the amount of PGE2 release decreased over later time intervals
with all LPS preparations, so that by 72 hours Salmonella was the only LPS
which resulted in significant Stimulation of PGE2 release over control
medium.
Table 2 demonstrates the results from experiments which examined
the relative potency of Wolinella recta LPS. A.a. and Salmonella were used
as reference LPS preparations. The data indicate that Wolinella was the most
12
PGE2 RELEASE (ng/ml)
Time intervals (hours)
LPS (10ug/rnl) 0 -24 24-48 48 72
Mean+ SEM Mean+ SEM Mean+ SEM
Control .30 + .16 .14 + .05 .07 + .02
Salmonella A5.64 + 1.17a,c,d A3.64 + 1.12a,d B.87 + .31a,d
A.a. A3.18 + .65b,c,d A1.51 + .38b,d .21 + .07b,c
B. intermedius A2.55 + .63a,b B .99 + .33a,b .19 + .07b
B. gingivalis A .78 + .20a,b .32 + .16 .06 + .02a
A p < .01 vs Control
B p < .05 vs Control
a= p < .05 vs A.a.
b= p < .05 vs Salmonella
c= p < .05 vs B. gingivalis
d= p < .05 vs B. intermedius
Data are the means + SEM for 6 experiments except for B. gingivalis LPS
which represents 5 experiments. Statistical test is paired students T-test.
TABLE2. PGE2 RELEASE (ng/ml)
LPS (10ug/ml) 0-24
Time intervals (hours)
24-48 48- 72
Mean + SEM Mean + SEM Mean + SEM
Control 3.06 + .93 2.10 + .71 .24 + .04
Salmonella A7.01 + 1.68a B 5.18 + 1.56a,c 3.09 + 1.21c
B4.32 + 1.24b,c 2.76 + 1.01b,c B .88 + .27c
Wolinella B6.94 + 1.95a A 8.82 + 1.20a,b A7.30 + 1.17a,b
A p < .01 vs Control
B p < .05 vs Control
a= p< .05 vs A.a.
b= p < .05 vs Salmonella
c= p < .05 vs Wolinella recta
Data are the means + SEM for 3 experiments. Statistical test is paired students t-
test.
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potent LPS tested. During the 0-24 hour interval Wolinella and Salmonella
lipopolysaccharides had stimulated similar amounts of PGE2 release,
however, over the 24- 48 and 48-72 hour intervals the Salmonella response
decreased while Wolinella increased to a point where the differences were
statistically significant. It is important to note that the control release in this
set of experiments was higher than that found in Table 1. However, the
relative differences between the Salmonella and A. a. were consistent.
DISCUSSION
In the present study, we have compared the relative potencies of the
lipopolysaccharides extracted from B. gingivalis, B. intermedius, Wolinella
recta, and A. actinomycetemcomitans in the ability to stimulate the release of
PGE2 from human monocytes. Salmonella LPS was used as a reference, since
its structure and potency have been extensively characterized (16). According
to our results, the LPS from Wolinella was consistently more potent than
that of the other periodontal organisms examined. Furthermore, the
Wolinella LPS response was sustained over all three 24 hour intervals while
a diminished response was observed with all other preparations over time.
.In contrast, the LPS prepared from B. gingivalis, B. intermedius, and A. a
were all shown to be less potent than either Salmonella or Wolinella. This
finding is consistent with previous studies which demonstrated Bacteroides
LPS to be weak relative to Salmonella in the stimulation of osteoclast-
mediated bone resorption (24), the localized Schwartzman reaction (36,69),
limulus lysate gelation (36), and pyrogenicity (41). In a study by Kiley and
Holt (26), LPS from A.a. was also shown to be less potent then Salmonella
when bone resorption activities were compared.
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The differences observed between the LPS preparations, examined in
this study, may result from structural and chemical differences between each
preparation. According to several reports, Bacteroides possesses a unique LPS
in that it lacks the acid labile keto-deoxyoctonic acid (KDO) and other heptose
residues characteristic of enterobacterial LPS preparations (36,41,69). A.a., on
the other hand, has been reported to contain KDO residues, indicating that
the relatively weak potency of this LPS preparation may be related to other
factors (4). Accordingly, the fatty acid composition of A. a. has been shown to
be substantially different from Salmonella LPS (4). The chemical composition
of Wolinella LPS has not yet been characterized. Although structural
differences may contribute to the relative potencies of LPS preparations, the
complexity and heterogeniety of LPS preparations makes analyses of structure
versus function highly speculative. Furthermore, the effect of the different
extraction procedure used to prepare Wolinella LPS has not been established.
However, a more detailed analysis of Wolinella LPS structure appears to be
warranted in light of its high potency in stimulating PGE2 release.
Protein contaminants associated with LPS preparations may participate
in monocyte activation processes. Consistent with previous reports
.characterizing lipid A-associated protein in E. coli and Salmonella LPS
preparations (40,67), our results demonstrate that Bacteroides and Salmonella
LPS contain detectable levels of protein. Although the effect of lipid A-
associated protein on monocyte secretory function remains to be established,
protein contaminants are undoubtedly associated with LPS and may
contribute to solubility and diffusion characteristics of LPS at disease sites.
Furthermore, it is unlikely that LPS released from bacterial cell walls is free of
protein contaminants from the cell wall. Additional work is required to as-
sess these possibilities.
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Although the 10 ug/ml dose of LPS was the only dose reported in the
present study, dose response characteristics have been examined for each LPS
preparation at 1 ng/ml, 100 ng/ml, and 10 ug/ml concentrations. All the LPS
preparations demonstrated increased responses with increased doses of LPS
with 10 ug/ml being the most potent. However, at the 1 ng/ml dose, only
Salmonella and Wolinella LPS stimulated PGE2 release to a greater extent
than controls.
In this report, we have demonstrated that all LPS preparations tested
stimulate the release of PGE2 from human monocytes. That this process may
occur in gingival connective tissue is strongly suggested by the ability of LPS
to penetrate sulcular epithelium (59), the increased numbers of monocytes in
periodontally diseased tissues (58), and the elevated levels of PGE2 in perio-
dontal tissues (18,34,38) and crevicular fluid (44) associated with diseased sites.
The sustained potency of Wolinella LPS for up to 72 hours was a unique
finding. Recent work in our laboratory has indicated that PGE2 release from
LPS stimulated monocytes may be potentiated by pretreatment with gamma
interferon (42), a product of T lymphocytes. Furthermore, we have found that
gamma interferon cotreatment with LPS results in sustained and potentiated
.PGE 2 release from monocytes treated with Bacteroides LPS (Chapter 3).
Surprisingly, under identical conditions, Salmonella LPS was only slightly
affected by gamma interferon. The apparent sustained potency of Wolinella
LPS, in the absence of gamma interferon, demonstrates a potentially
significant mechanism by which this LPS may be more pathogenic. Further
studies are in progress to examine this possibility.
CHAPTER 2
IFN-/potentiation of lipopolysaccharide-induced eicosanoid release from
human monocytes.
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ABSTRACT
Interferon- (IFN-,) can act to potentiate lipopolysaccharide (LPS)-
stimulated processes in mononuclear phagocytes, including interleukin-1
release and tumoricidal activity. The present investigation examined the
capacity of (IFN-) to modulate LPS-stimulated prostaglandin E2 (PGE2) and
thromboxane B2 (TxB2) release from counterflow isolated human monocytes.
The release of PGE2 and TxB2 was compared for cells incubated with IFN-/
prior to treatment with LPS and for cells treated simultaneously with IFN-,
and LPS. Treatment of cells with IFN-/prior to stimulation with LPS (10
g/ml, Salmonella typhimurium ) resulted in elevated prostaglandin E (by
immunoassay) and [3H] PGE2 release from monocytes when compared with
cultures treated with LPS alone. In contrast, IFN-, pretreatment did not
potentiate labeled or immunoreactive TxB2 release from LPS-treated
monocytes. IFN-/ pretreatment without LPS stimulation did not result in
elevated eicosanoid release over controls. In addition, continuous treatment
of monocytes with both IFN-/and LPS did not result in greater release PGE2
and TxB2 than the summed individual effects of IFN- and LPS. These results
indicate that IFN-/selectively potentiates LPS stimulated arachidonic acid
conversion to PGE2 and not TxB2 in human monocytes. This effect was
observed only for monocytes pretreated with IFN-/prior to stimulation with
LPS.
INTRODUCTION
Recent evidence has demonstrated the capacity of interferon- (IFN-/)
to potentiate bacterial lipopolysaccharide (LPS)-stimulated secretory responses
in monocytes and macrophages, such as the secretion of interleukin-l(2).
Although LPS is recognized as a potent stimulator of eicosanoid release from
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monocytes and macrophages, little is known concerning the effect of IFN-, on
LPS-mediated eicosanoid release from monocytes. Previous investigations
have generally characterized prostaglandin release by pretreating cells with
IFN-/prior to activating with a secondary stimulus (3,22). High doses of IFN-
(1,000 U/ml) have been shown to increase prostaglandin E2 (PGE2) release
from macrophages treated with phorbol myristate acetate (PMA) and A-23187
but not zymosan (3). In contrast, IFN-/(1U/ml) was reported to be ineffective
in promoting elevated release of PGE2 following treatment of macrophages
with PMA (22). From these results, IFN-, demonstrates a variable capacity to
potentiate prostaglandin release from stimulated macrophages depending on
IFN-t dose and the secondary stimulus. However, initial exposure to IFN-/
followed by a secondary stimulus may have little relevance to the process of
macrophage activation in the pathogenesis of chronic inflammation. Instead,
macrophages recruited to sites of LPS-elicited chronic inflammation are likely
to be stimulated simultaneously with IFN- released locally from activated T
lymphocytes. The present investigation, therefore, compared the effects of
simultaneous and sequential treatment with IFN- on LPS-mediated PGE2
release from monocytes.
Human monocytes stimulated with LPS release other cyclooxygenase-
derived products of arachidonic acid, such as thromboxane B2 (TxB2) (56).
Furthermore, release of TxB2 is quantitatively greater than PGE from
counterflow-separated monocytes during early phases of treatment with LPS
(57). Because TxB2 and PGE2 are derived from a common substrate,
arachidonic acid, and are released in elevated amounts from monocytes
treated with LPS, it was of interest to examine IFN-, effects on TxB2 release in
addition to PGE2.
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METHODS AND MATERIALS
Materials’[3H8] Arachidonic acid (sp. act., 83.8 Ci/mmole), [3H8] TxB2
and [3H7] PGE2 were obtained from New England Nuclear. PGE2 2-p-
toluidinylnaphthalene 6-sulfonate, penicillin, and streptomycin were
obtained from Sigma Chemical Co. Anti-PGE2 and anti-TxB2 were obtained
from Seragen and defined fetal calf serum was obtained from Hyclone Labs.
Bacterial lipopolysaccharide (Salmonella typhimurium )was obtained from
Difco Laboratories and recombinant human IFN-/ was obtained from Amgen
Biochemicals.
Cell Isolation and Culture" Citrated fresh human blood, obtained by
venipuncture, was separated by Ficoll-Hypaque density gradient
centrifugation to yield a mononuclear cell fraction. This fraction was then
subjected to counterflow centrifugation (53), during which platelets and
lymphocytes were removed to yield a highly enriched population of
monocytes, as previously described (56). Monocytes were then pelleted in Ca-
Mg-free phosphate-buffered saline with 1% autologous plasma.
The cells were then resuspended in a known volume of MCDB 104
medium (37) containing 1% heat-inactivated fetal calf serum, 100 U/ml
penicillin, and 100 ug/ml streptomycin, and monocyte recovery was
determined by electronic counting (Coulter Electronics). The cell suspension
was then diluted to achieve a concentration of 1.0 X 106 cells/ml, and 1-ml
aliquots were placed in plastic (Falcon, 16-mm) culture dishes. All
incubations were carried out at 37oC in the presence of 5% CO2/95% air.
After 2 h, medium was exchanged twice to remove nonadherent cells, and
culture treatments were initiated. For experiments evaluating labeled
metabolite release, labeled arachidonic acid was added to culture medium
under conditions described in the Results section.
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RIA for PGE2 and TxB2 PGE and TxB2 levels in culture supernatants
were determined by immunoassay utilizing competitive adsorption to
dextran-coated charcoal (according to Seragent technical bulletin). All
determinations were carried out in duplicate and the average counts for each
pair used to calculate PGE and TxB2 levels. Regression coefficients for logit-
log-transformed standard curves were generally greater than 0.990. Because
the antioPGE2 antibody demonstrated 100% cross-reactivity with PGE1 at 50%
bound/total, immunoassay results were described in terms of ng/ml PGE
released.
Labeled Arachidonic Acid Metabolite Extraction and Separation
Arachidonic acid metabolites were extracted by first adjusting the pH of
culture supernatants to 3.5 with formic acid (70%) followed by 3 X 3-ml
washes with ethyl acetate. The combined organic extracts were evaporated to
dryness under vacuum and stored at -20 C under nitrogen. Prior to thin-
layer chromatography, arachidonic acid (5 rag), PGE2 (5 rag) and TxB2 (5 rag)
were added to each sample and the contents dried under a stream of nitrogen.
Individual samples were dissolved in 10 ml of chloroform, vortexed, and
spotted on silica gel G plates (precoated 200 mm, LHP-K plates, Whatman).
This was followed by three additional washes with 5 ml of chloroform,
spotting each wash immediately below the previous application. Plates were
then developed in one dimension with chloroform/methanol/acetic
acid/H20(90:8"1"0.8, vol/vol) (71). After drying, plates were sprayed with
fluorescent indicator (lmM 2-p-toludinylnaphthalene 6-sulfonate in 50 mM
Tris, pH 7.4) and the lipid spots visualized with ultraviolet light. Arachidonic
acid metabolites were identified by comigration with authentic standards (Rf
values for arachidonic acid, 0.80 + 0.02; TxB2,0.40 + 0.01; and PGE2,0.512 +
0.01, n 4), after which spots were scraped and counts determined.
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Determination of Cell DNA Content" DNA content of adherent
monocytes was determined after harvesting culture medium at 72 h. Cells
were treated with 0.5 ml of 5 mM Na0H and sonicated briefly. After a 24-h
period, 100 ml was assayed for DNA content by the 4’,6-diamidino-2-
phenylindole fluorometric assay of Brunk et al (5).
RESULTS
Table 1 demonstrates the release of immunoreactive PGE from human
monocytes treated simultaneously with LPS and IFN-t. As shown, the release
of PGE is maximally stimulated during the 24 to 48 h culture period followed
by a modest decrease in the rate of release. IFN-), had no significant effect on
PGE release when administered alone or together with LPS. DNA levels
recovered at 72 h from monocyte cultures were as follows: 7.41 + 0.25, 10.18 +
0.15, 9.53 + 0.93, and 8.35 + 0.15 ng/culture well for control, IFN--, LPS-, and
LPS + IFN--treated cultures, respectively.
TABLE 1. PGE RELEASE FROM MONOCYTES TREATED WITH IFN-/AND LPS
PGE (ng/ml)
Control IFN-y b Lpsa IFN-y + LPS
0-8 hours 0.38 + 0.15 0.63 + 0.24 2.89 + 0.16 3.04 + 0.38
8 -24 hours 1.27+ 0.40 1.19 + 0.39 3.62 + 0.72 2.70 + 0.33
24 48 hours 0.30 + 0.30 0.84 + 0.67 5.79 + 1.95 5.80 + 1.58
48-72 hours 0.27+ 0.09 0.74 + 0.23 3.94 + 1.10 4.86 + 0.75
Data represent the mean + standard error for 6 determinations
Monocytes were inoculated at 106 cells/ml in 16mm wells and treated with indicated
media. Media were exchanged at 8, 24, and 48 hrs and replaced with identical fresh media.
a 10 g/ml LPS (Salmonella typhimurium
b10 U/ml IFN-/.
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Table 2 demonstrates the release of immunoreactive PGE from
monocytes cultured for 48 h with or without IFN- followed by treatment
with control medium or LPS (10 mg/ml) for an additional 24-h period.
Control cultures demonstrated peak PGE release during the 8 to 24 h time
interval with diminished release thereafter. Treatment of monocytes at 48 h
with LPS produced a twofold stimulation of PGE release over controls. IFN-,
(10 U/ml) alone produced no significant effect on PGE release when corn-
pared with control cultures. IFN- was not included in culture medium from
48 to 72 in these experiments. Finally, treatment of monocytes with LPS after
48 h of exposure to IFN-, treatedmodul in a 10-fold stimulation of PGE release
over IFN- treated cultures and a sevenfold stimulation over LPS-treated
cultures. DNA levels recovered at 72 h from monocyte cultures were as
follows: 4.45 + 0.18, 6.93 + 0.27, 5.71 + 0.21, and 7.84 + 0.48 ng/culture well for
control, IFN-/-, LPS- and IFN-, + LPS-treated cultures, respectively.
TABLE 2. PGE RELEASE FROM MONOCYTES TREATED WITH IFN-/FOLLOWED BY LPS
PGE (ng/ml)
Time Interval Control IFN-/(10 U/ml)
0-8 hr. 0.55 + 0.17 0.75 + 0.36
8-24 hr. 2.01 + 0.12 1.67 + 0.13
24-48 hr. 0.86 + 0.13 0.84 + 0.35
Treatment at Control LPS IFN-/ LPS
48 hr. (10g/ml) (10g/ml)
48-72 hr. 0.29 + 0.02 0.70 + 0.18 0.56 + 0.23 5.15 + 1.04
Data represent the mean + standard error for 4 experiments
Monocytes plated as in Table 1. Where indicated, cells were treated with IFN- from 0-
48 hrs. LPS treatment occured during the 48-72 hr interval. Medium was exchanged at the end
of each interval.
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Table 3 demonstrates the release of labeled PGE2 and TxB2 from
monocytes labeled with [3H]-arachidonic acid. Labeling with [3H]-arachidonic
acid occurred while cells were adhering to culture dishes (2 h), after which
unincorporated label was removed through rinsing and cells treated with the
indicated stimulants. IFN- alone (10 U/ml) did not stimulate the release of
labeled PGE2 compared with controls and only slightly elevated labeled TxB2
release. Continuous treatment of monocytes with LPS resulted in fourfold
stimulation of labeled PGE2 release which diminished to approximately
twofold by 72 h. Threefold stimulation of labeled TxB2 release was observed
during the 0 to 8 h interval and no stimulation over controls thereafter.
Continuous treatment with LPS and IFN-/did not elevate PGE2 release over
LPS alone and only slightly elevated TxB2 release. However, IFN-,
pretreatment followed by LPS resulted in twofold stimulation of PGE2 release
over cells not pretreated with IFN-/and sixfold stimulation over cells treated
with IFN-/alone. TxB2 release was elevated approximately threefold in
cultures treated with LPS and was not affected by IFN-, pretreatment.
The time course of PGE2 and TxB2 release during the 48 to 72 h culture
period are demonstrated in Fig. 1. For labeled eicosanoid release, monocytes
were labeled with [3H]arachidonic acid during the first 24 h of culture. Cells
were then rinsed with unlabeled fresh medium and treated with either
control medium or medium containing 10 U/ml IFN-. At 48 h, monocyte
cultures were treated as shown and medium exchanged at 50, 56, and 64 h and
harvested at 72 h. Therefore, each histogram bar represents metabolite release
only during the indicated interval. Cultures treated with IFN- followed by
LPS demonstrated potentiated PGE and PGE2 release when compared with
cultures treated only with LPS. IFN-/potentiation of prostaglandin release
was maximal during the 64 to 72 h interval. IFN-, alone, did not elevate PGE
Table 3. EFFECT OF IFN-/TREATMENT ON PGE2 AND TxB2 RELEASE FROM LPS-TREATED
MONOCYTES
Labelled eicosanoid release (cpm / sample
Time Interval
0-8 hours 8-24 hours 24-48 hours 48-72 hours
PGE2
Control 220 + 42 239 + 4 102 + 19 25 + 9
Control (0-48 hr.) 77+47
+ LPS (48-72)
IFN-y 206 + 22 234 + 20 119 + 25 27+ 15
IFN-y (0-48 hr.) 151 + 40
+ LPS (48-72)
LPS (0-72 hr.) 807 + 46 318 + 10 215 + 7 41 + 33
LPS + IFN-/ 862 + 86 410 + 10 288 + 59 44 + 31
(0-72 hr.)
TxB2
Control 684 + 99 614 + 73 157+ 25 56 + 19
Control (0-48 hr.) 140 + 77
+ LPS (48-72)
IFN-T 763 + 73 748 + 96 188 + 46 46 + 40
IFN-/ (0-48 hr.) 149 + 53
+ LPS (48-72)
LPS (0-72 hr.) 2043 + 241 611 + 19 145 + 9 42 + 41
LPS + IFN-y 2343 + 27 721 + 4 261 + 41 70 + 28
(0-72 hr.)
Data represent the mean + standard error for 4 determinations
Cells from two donors were labeled with 0.1 Ci/ml [3H]arachidonic acid during cell
adherence to culture dishes (2 h) after which the cells were washed twice with unlabeled
medium. Treatment of cultures with the indicated agents was initiated at this time (indicated
as time 0) and medium was exchanged at 8, 24, and 48 hrs. Each determination represents
labeled eicosanoid extracted from replicate pooled culture supernatants.
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release over untreated controls. IFN-/pretreatment also did not markedly
affect LPS stimulation of labeled and immunoreactive TxB2 release. In
addition, LPS-stimulated TxB2 release diminished almost to control levels
during the 64 to 72 h interval, whereas, PGE2 release remained at an elevated
level with IFN-/ treatment. DNA recovered at 72 h from monocyte cultures
was as follows: 4.99 + 0.41, 5.53 + 0.56, 6.34 + 0.77, and 6.60 + 0.92 ng/culture
well for control, IFN-,-, LPS-, and IFN-/+ LPS-treated cultures, respectively.
Figure 2 demonstrates the effect of varying concentrations of IFN-, on
[3H]PGE2 and immunoreactive PGE release from LPS- (10 mg/ml) treated
monocytes. Labeled PGE2 release was elevated over controls by approximately
10-fold with 1,000 U/ml IFN-/, whereas, immunoreactive PGE release was
elevated by approximately 50-fold. IFN-/ at concentrations of 1 U/ml or less
demonstrated no potentiation of LPS-mediated prostaglandin release. The
minimum dose of IFN-/that elevated PGE2 release was 10 U/ml. Relative to
[3H]PGE2, release of [3H]TxB2 was only moderately stimulated with higher
doses of IFN- (data not shown in Fig. 2). Labeled TxB2 release was 807 + 69,
664 + 15, and 291 + 38 cpm/2ml for 1,000, 100, and 10U/ml IFN-/, respectively.
IFN-, doses of I U/ml or less did not promote elevated [3H]TxB2. release over
cultures treated with LPS alone (137 + 24 cpm/2ml). As with PGE2 release, 10
U/ml IFN-/was the minimum dose that elevated TxB2 release. DNA levels
recovered from control cultures were 10.83 + 0.74 ng/culture well whereas
cultures pretreated with the lowest to highest levels of IFN-/were as follows:
14.29 + 0.86, 10.72 + 1.32, 10.63 + 1.41, 5.22 + 1.43, 7.89 + 2.72, respectively.
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Figure. 1 Time course of PGE2 and TxB2 release from LPS-treated monocytes. For [3H]
eicosanoid release, monocytes were labeled from 0-24 hours with 0.1gCi/ml [3H]arachidonic
acid. Cells then received the following treatments: (i) Control medium (24-72 h) (ii) 10
U/ml IFN-/(24-48 h) followed by control medium (48-72 h), (iii) control medium (24-48 h)
followed by 10 mg/ml LPS (48-72 h) [, (iv) 10 U/ml IFN-/(24-48 h) followed by 10 mg/ml
LPS (48-72 h). Medium was exchanged at 48, 50, 56, 64, and 72 h. Histogram bars represent
metabolite release during the indicated intervals. Results are expressed for eight trials from
three experiments. PGE2 and PGE release from IFN- + LPS-treated cultures were significantly
elevated over LPS-treated cultures (by t-statistic for two means: a, p < 0.025; b, p < 0.05).
27
60-
PGE
RIA (ng/ml)
(48-72 Hrs)
4O
3O
2O
I0
RIA (ng/ml)
. TLC (cpm)
’0’IControl .1 0 O0 1000
IFN DOSE
Units/ml
2OOO
PGE2
TLC (cpm)
(48-72 Hrs)
Figure 2. Effect of increasing levels of IFN-T on LPS-mediated release of PGE2. Monocytes
were labeled from 0-24 h with 0.1 Ci/ml [3H]arachidonic acid followed by rinsing to remove
unincorporated label. Cells were then treated with IFN-T at the indicated levels from 24-48
hrs followed by replacement with control medium or medium containing LPS (10 g/ml).
Mtabolite release was measured only for the 48 -72 h media samples. [3H] PGE2 and PGE
release are shown as the mean + standard error for two trials. Treatment of monocytes with
IFN-T alone did not significantly elevate PGE2 of PGE release over control cultures during the
48-72 h interval.
DISCUSSION
This investigation demonstrates the importance of simultaneous
versus sequential treatment with IFN- and LPS in promoting PGE2 release
from human monocytes. Monocytes treated continuously with IFN- and
LPS released only slightly greater levels of labeled PGE2 (Table 3) than
monocytes treated with LPS alone. Release of immunoreactive PGE (Table 1)
under identical treatment conditions was not affected in a consistent manner.
Because IFN-, alone slightly elevated PGE2 release from human monocytes,
these results could reflect an additive effect of the two agents. However,
preexposure to IFN-7 for 24-48 h followed by LPS treatment resulted in a
pronounced increase in PGE2 release, whereas, IFN-7 alone had no effect
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during the same time period. These results cannot be reconciled on the basis
of a simple additive effect of the two agents and indicate that IFN- acts to
modify monocyte secretory responses through different mechanisms than
LPS. Although emerging evidence now suggests that IFN- modulates
protein kinase C activity (21), there is little evidence reported concerning the
mechanisms by which LPS and IFN-/ mediate alterations in monocyte
secretory function.
As noted with PGE2 release, [3H]TxB2 release with continuous IFN-,
and LPS treatment was slightly elevated over LPS alone. In contrast to PGE2,
labeled and immunoreactive TxB2 release were not potentiated with IFN-/
pretreatment. This finding indicates that 10 U/ml IFN- can selectively
stimulate the conversion of arachidonic acid to PGE2 following treatment
with LPS. However, higher doses of IFN-, were shown to promote LPS-
mediated TxB2 release but not to the same extent as labeled PGE2 release. Our
results are in contrast to a recent report demonstrating unchanged or slightly
elevated thromboxane release and reduced PGE2 release from Listeria mono-
cytogenes-elicited macrophages compared with resident macrophages (70).
Sustained TxB2 synthesis from Listeria-elicited macrophages was proposed to
result from IFN-/interaction with elicited cells. Our results clearly indicate
that IFN-/selectively potentiates PGE2 release over TxB2 release from LPS-
treated human monocytes.
After 72 h in culture, DNA levels recovered from adherent monocytes
were found to vary, but not in a consistent pattern following specific
treatments. Although all experiments were carefully controlled to assure
inoculation of 1 X 106 cells/culture well, cell retention over 72 h was variable
from donor to donor. Some variable cell adherence has been noted over a
much larger group of experiments conducted in this laboratory. In most
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cases, release of eicosanoids from monocyte cultures did not correlate with
DNA levels recovered from cultures. Most striking was the increased cell
adherence with lower doses of IFN-, whereas higher doses of IFN-/reduced
cell adherence after LPS stimulation (Fig. 2). In contrast, PGE2 release was
markedly elevated only for cultures treated with higher doses of IFN-,. This
observation suggests that elevated eicosanoid release is regulated primarily by
adherent monocytes and may reflect differential effects of IFN-, on specific
populations of monocytes.
The potentiation of PGE2 release demonstrated by IFN-/ in this
investigation was consistent with previously reported effects of IFN-/on
monocyte/macrophage function. IFN- has been shown to prime
macrophages for LPS-mediated tumor cell killing (47), and IFN-, can restore
time-dependent reduction of interleukin-1 secretion from LPS-treated
monocytes (2). In addition, the lack of a significant stimulation of PGE2
release by monocytes treated with IFN-/ alone was also consistent with
previous reports demonstrating that macrophage tumor cell killing and
interleukin-1 release were not elevated by treatment with IFN-/alone. A
dose of 10 U/ml IFN-, was utilized in most experiments since this dose has
been shown to promote maximal tumor cell killing with mouse macrophages
(47) and to exceed by one order of magnitude the dose necessary for maximal
stimulation of arachidonic acid release from mouse macrophages treated with
PMA (22). In the present investigation, IFN-/levels greater than 10 U/ml
demonstrated increased potential to promote LPS-mediated PGE2 release.
IFN-, potentiation of LPS-mediated PGE2 release was most prominent with
sequential treatment conditions, suggesting that simultaneous exposure to
IFN-, and LPS in sites of chronic inflammation may not lead to significantly
greater eicosanoid release than with LPS alone. It should be emphasized that
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these results apply to Salmonella typhimurium LPS and may not reflect
effects by other LPS preparations. Experiments in our laboratory are directed
at further examining PGE2 release from monocytes simultaneously treated
with IFN- and other LPS preparations.
CHAPTER 3
Gamma interferon modulation of prostaglandin E2 release from monocytes
stimulated with lipopolysaccharides from Bacteroides gingivalis, Bacteroides
intermedius and Salmonella typhimurium.
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ABSTRACT
Lipopolysaccharides (LPS) from Bacteroides species have been shown
to be relatively weak in comparison to that of enterobacteria such as
Salmonella, when examined by pyrogenicity, bone resorption, and the
localized Schwartzman reaction. This is contrary to the proposed pathogenic
role of Bacteroides species in the etiology of diseases such as adult
periodontitis. In this investigation, the relative potency of LPS from
Bacteroidesgingivalis and intermedius were compared to that of
Salmonella, with respect to the stimulated release of PGE2 from human
monocytes. Furthermore, the effect of recombinant gamma interferon was
examined for possible potentiation of the LPS response. Monocytes, separated
by counterflow centrifugation, were exposed to LPS ( 1 ng/ml, 100 ng/ml and
10 ug/ml) alone or in combination with gamma interferon (10 Units/ml).
PGE2 levels in culture medium were determined by radioimmunoassay for
medium samples exposed to monocytes over the following time intervals: 0-
8, 8-24, 24-48, and 48-72 hours.
Although IFN-/did not stimulate PGE2 release alone, the amount of
PGE2 released from monocytes stimulated with Bacteroides species LPS was
significantly increased when monocytes were cultured concomitantly with
IFN-,. PGE2 release elicited by Salmonella LPS was not significantly affected
by the addition of interferon. Differences were observed in the relative
potency of the three LPS preparations tested; Salmonella LPS stimulation
resulted in approximately 2-3 times the PGE2 release as Bacteroides species
LPS. This difference was minimized, however, with interferon cotreatment.
It is concluded that gamma interferon can increase the release of PGE2 from
Bacteroides LPS-stimulated monocytes and that this effect can partially
overcome the observed weakness of these LPS preparations.
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INTRODUCTION
Numerous gram-negative bacteria, particularly the enterobacteria,
possess lipopolysaccharides which are similar in general structure and
endotoxic activity (52). However, LPS extracted from some of the
Bacteroidaceae, particularly Bacteroides intermedius and gingivalis, lack
particular chemical constituents commonly found In enterobacterial LPS
(36,41,69). Furthermore, in tests of pyrogenicity (41), the localized
Schwartzman reaction (36,69), limulus lysate gelation, chick embryo lethality
(36), and bone resorption (24), LPS from Bacteroides species have been shown
to be relatively weak in comparison to a standard enterobacterial LPS, such as
Salmonella typhimurium. The apparent weakness of Bacteroides LPS does
not support a significant role of LPS from these species in periodontal
pathogenesis, yet these organisms are closely associated with progressive
attachment loss in humans. Furthermore, enterobacterial lipopolysaccharides
have been shown to stimulate the release of numerous biologically active
substances from monocytes, particularly prostanoids and cytokines (2,17,55);
however, investigations into Bacteroides LPS stimulation of prostanoid
release have been lacking. Because prostaglandin E2 (PGE2) is a prominent
secretory product of monocytes (55) which can mediate inflammatory and
immune responses as well as bone resorption (17,65), one of the aims of this
investigation was to compare and partially characterize the capacity of B.
intermedius and B. gingivalis LPS preparations to stimulate PGE2 release,
relative to that of Salmonella.
Gamma interferon (IFN-/) has been shown to produce a number of
direct effects on monocytes, including increased expression of Fc receptors
(20,49) and Ia antigen (27). Furthermore, interferon has the ability to
modulate both tumoricidal activity (47) and interleukin 1 release (2) when
34
monocytes are treated with LPS. Although monocytes do not release IFN-/,
LPS-treated monocytes have been shown to elevate IFN-/release from T
lymphocytes (30). Therefore, LPS-mediated responses in monocytes are
subiect to modification by IFN-/ when stimulated in the presence of T
lymphocytes. Such conditions are likely to exist with established lesions of
chronic adult periodontitis. Although we have recently demonstrated that
IFN- pretreatment greatly enhanced PGE2 release from monocytes
secondarily treated with Salmonella LPS (42), no data exists concerning IFN-,
potentiation of LPS stimulated PGE2 release from monocytes simultaneously
exposed to IFN-/and LPS. Furthermore, examination of IFN-/effects upon
Baceroides LPS stimulation have not been reported. Therefore, a second
aim of this investigation was to characterize and compare the effects of IFN-,
on the release of PGE from monocytes stimulated with LPS extracted from
Baceroides inermedius and gingivalis, in comparison to Salmonella y-
phimurium.
METHODS AND MATERIALS
Cell Separation Monocytes were separated from whole venous blood
of random human donors by ficoll-Hypaque sedimentation (400 x g x 35 min.)
at 10oc. The mononuclear leukocyte rich fractions were collected, diluted,
and washed two times in Ca++ and Mg++ free, phosphate buffered saline
(PBS) (125 x g x 15 min.) at 10oc. The cells were then counted electronically
(Coulter Electronics) and monocyte enrichment achieved by counterflow
centrifugation (Beckman Instruments). Autologous plasma (1%) was then
added and monocytes sedimented (125 x g x 15 min.) and resuspended in
MCDB 104 medium (37) supplemented with 1% defined heat inactivated fetal
calf serum (Hyclone), 100 U/ml penicillin and 100 mcg/ml streptomycin.
Cells were counted and plated in plastic (Falcon Plastics) 16mm wells (106 cells
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per well). At 2 hours the cells were washed two times in medium to remove
any non-adherent cells. Cultures were incubated at 37oc in an H20 saturated
5% CO2 atmosphere. Cell viability was routinely confirmed by trypan blue
exclusion.
LPS and IFN-y Preparations" LPS was obtained from the following
bacterial strains" Salmonella typhimurium (Difco Laboratories), Bacteroides
gingivalis and Bacteroides intermedius (kindly provided by Dr. Stan Holt,
University of Texas Health Center at San Antonio). All LPS were prepared by
the hot phenol-water method of Westphal and Jann (76). Recombinant IFN-/
was purchased from AMGEN Biochemicals with a specific activity of 1.6 x 107
Units/mg protein calibrated against NIH IFN- standard GG-23-901-530.
LPS Analysis" Protein content of the LPS preparations was assayed by
the method of Lowry (35). Albumin (Fraction V, Pentax) was used as a
standard. LPS preparations were subjected to SDS-PAGE in order to assess
relative molecular weight of LPS associated proteins.
Experimental Conditions" Treatments consisted of the following: LPS
(in concentrations of 1 ng/ml, 100 ng/ml, and 10 ug/ml), with or without
IFN- (10 Units/ml), IFN-, alone (10 Units/ml), and control medium. Media
were exchanged at 8, 24, 48, and 72 hours and the supernatants assayed for
PGE2 content. Adherent cells retained in culture wells after the 72 hour
media change were assayed for DNA content by the method of Brunk et al.
(5). No significant differences were observed between the various treatments
with respect to DNA levels.
Assay for PGE2 Levels of PGE2 in the culture supernatants were
assayed by radioimmunoassay using absorption to dextran-coated charcoal.
Anti-PGE2 antibody and 3H-PGE2 were purchased from Seragen and New
England Nuclear, respectively. The anti-PGE2 antibody demonstrates 100%
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cross-reactivity with PGE, however, other investigations in this laboratory
have demonstrated that the E series prostaglandin released from human
counterflow isolated monocytes consists of >97% PGE2 when assayed by gas
chromatography-mass spectrometry (manuscript submitted). The PGE2
levels in culture supernatants were extrapolated from PGE2 standard binding
utilizing logit-log transformation.
Data Analysis" Differences between treatment means were tested by
the independent-samples paired t-test. Data presented are from 3 experiments
except where noted.
RESULTS
LPS analysis" Salmonella, B. intermedius, and B. gingivalis LPS
preparations were found to contain 5.1%, 6.9%, and 11.9% protein,
respectively, as assessed by Lowry assay. LPS associated proteins were assessed
by SDS-PAGE. Most contaminating proteins were of low relative molecular
weight (< 20,000), particularly with the B. intermedius LPS. Salmonella LPS,
purchased from Difco, contained a variety of protein fragments of relative
molecular weights ranging from 60,000 to < 14,000.
Effect of IFN-, on LPS stimulation of PGE2 release" The addition of
IFN-, to LPS from either Bacteroides species resulted in greater release of
PGE2 than LPS alone, as shown in Figures 1 (B. intermedius ) and 2 (B. gingi-
valis ). Interferon treatment alone did not significantly stimulate PGE2
release over controls,indicating that enhancement of PGE2 release with
interferon and LPS is not due to an additive effect of the two agents.
Interferon potentiation was evident at all time intervals, except the 8-24 hour
interval for B. gingivalis. During the 0-8 hour interval, the addition of 10
Units/ml of recombinant interferon to LPS (100 ng/ml and 10 ug/ml ) from
B. gingivalis and intermedius resulted in significantly increased (p< .05)
release of PGE2 when compared to LPS alone. During the 8-24 hour interval,
PGE2 release stimulated by B. intermedius (100 ng/ml and 10 ug/ml doses)
was significantly enhanced (p < .01 and p<.05, respectively) by IFN-. The
greatest potentiation of PGE2 release by interferon was exhibited with
Bacteroides LPS during the 24-48 hour interval. All doses of B. intermedius
and the 100 ng/ml and 10 ug/ml doses of B. gingivalis LPS resulted in
significantly increased (p< .01) release of PGE2 (compared to LPS alone) when
interferon was added. The effect of interferon was still evident at the 48-72
hour interval although only at the 100 ng/ml and 10 ug/ml doses (p< .05) for
both LPS preparations. It must be noted, however, that the amount of PGE2
released from the 100 ng/ml dose of B. gingivalis LPS with interferon was
not significantly different from that of interferon alone.
In contrast to Bacteroides LPS preparations, the addition of IFN-/had
no significant effect on Salmonella LPS stimulated PGE2 release (Figure 3),
although the mean levels of PGE2 released during the 48-72 hour interval
appeared greater with interferon.
The modest potentiation of Salmonella LPS stimulation was
examined further by evaluating the effect of increasing doses of interferon on
LPS (10 ug/ml) stimulated PGE2 release. Figure 4 demonstrates that higher
doses of IFN-, tended to increase Salmonella LPS stimulation of PGE2 release.
Although maximal PGE2 release was observed with 100 U/ml interferon, this
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Figure 1. Bacteroides intermedius LPS
Legend for Figures 1-3
Fig. 1 (Bacteroides intermedius ), Fig. 2 (Bacteroides gingivalis ), and Fig. 3 (Salmonella
typhimurium) illustrate amounts of PGE2 (ng/ml) released, Mean + S.E.M. from I x 106 cells/ml
exposed to the following doses of the respective LPS preparations over the indicated time
intervals: 1 ng/ml 100 ng/ml , 10 ug/ml , and control The unfilled column
superimposed behind each dose column represents data obtained from the respective dose of LPS
with the addition of IFN-T (10 Units/M). a= p<.01 b= p<.05
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Figure 3. Salmonella typhimurium LPS
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was associated with relatively high variability. In contrast, B. gingivalis LPS
with 100 U/ml of interferon resulted in approximately 4-fold greater PGE2
release compared to LPS alone. Salmonella LPS with 100 U/ml of interferon
resulted in less than 2-fold increased PGE2 release. It can also be noted that
interferon alone had minimal effect on PGE2 release.
C::CWTRMEDL /1/VTE /1A/.
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Figure 4. IFN-/Dose reponse
Cells were treated with control medium, or LPS (10 ug/ml) from the three bacteria, and
the indicated concentrations of IFN-y at time 0. Identical media was exchanged at 24
hrs and experiment terminated at 48 hrs. Data depicts the mean + SEM of PGE2
(ng/ml) released during the 24-48 hr time interval, data are from two experiments.
Capacity of LPS preparations to stimulate PGE2 release" Salmonella
(Figure 3) was the most potent LPS in stimulating PGE2 release. At all doses
and time intervals, treatment with Salmonella LPS resulted in greater PGE2
release than either Bacteroides
of LPS from each Bacteroides
LPS preparation. In contrast, a 1 ng/ml dose
species did not significantly stimulate PGE2
release over controls. Stimulation with increasing doses of LPS from
Bacteroides species resulted in dose responses which were reduced relative to
Salmonella LPS.
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When comparing lipopolysaccharides extracted from both Bacteroides
species, similar stimulation of PGE2 release was observed. However, 10
ug/ml was the only dose of B. gingivalis LPS which consistently resulted in
PGE2 release greater than controls. Also, the maximal or greatest effect of B.
gingivalis and intermedius LPS occurred during the 8-24 hour interval and
then gradually decreased, as opposed to that of Salmonella which attained
maximal stimulation during the 24-48 hour interval before declining.
DISCUSSION
Unique to the experimental design of this study was the use of
interferon and LPS concomitantly. This was thought to evaluate the effects of
these agents as they would likely interact in vivo during inflammatory
and/or immune responses. Previous reports have examined sequential
activation of monocytes to a tumoricidal level (47) by first pretreating with
interferon followed by administration of LPS. The same experimental design
has been applied to the examination of interferon effects on various
monocyte functions and have included different secondary stimuli, such as
calcium ionophore, zymosan, immune complexes, phorbol diesters, and LPS
(2,3,22). Although sequential activation of monocytes is relevant to the study
of cell differentiation, it is not likely to accurately simulate
microenvironmental conditions at sites of chronic inflammation, where cells
are simultaneously exposed to many stimuli present in the extracellular
environment. These differences were explored in a previous study which
demonstrated that IFN-/can potentiate PGE2 release from monocytes with
sequential treatment conditions but not with simultaneous treatment, using
Salmonella LPS(42).
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The experiments described herein have demonstrated two unique
aspects of IFN-, and LPS effects upon human monocyte release of
prostaglandin E2. First was the observed potentiation of PGE2 release by
simultaneous treatment with IFN-y and LPS. That this effect was primarily
associated with the LPS extracted from the Bacteroides species and not
Salmonella was the second important observation. Furthermore, this study
confirmed previous reports demonstrating the relative weak potency of
Bacteroides LPS. It has been hypothesized that the absence of keto-
deoxyoctonic acid and heptose in Bacteroides LPS may result in a structure
with weak endotoxic potential (36). However, the relationship between the
structure of Bacteroides species LPS and its biological activity has not been
fully elucidated at this time.
Interferon potentiated the effects of Salmonella LPS to a minimal
extent. This finding is in agreement with our previous study which showed
minimal to no enhanced release of both radioimmunoassayable and 3H-
labelled PGE2 from monocytes treated simultaneously with LPS and 10 Units
of IFN-7 (42). However, in the present study increased doses of IFN-y were
tested and shown to have greater enhancement of PGE2 release.
When maximal doses of LPS were compared, interferon potentiation
of Bacteroides LPS resulted in levels of PGE2 release which were comparable
to Salmonella LPS. This observation demonstrates a potentially significant
mechanism for increasing the release of PGE2 from cells exposed to a
relatively weak LPS in combination with products of activated lymphocytes.
The selective potentiation of Bacteroides LPS over Salmonella may reflect
inherent structural differences between the preparations or a maximal
stimulatory capacity of monocytes when exposed to interferon, regardless of
the LPS preparation. Another possibility is that protein contaminants
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associated with LPS preparations may participate in monocyte activation
processes. Consistent with previous reports characterizing lipid A-associated
protein in E. coli and Salmonella LPS preparations (40,67), our results
demonstrate that Bacteroides LPS contains detectable levels of low molecular
weight proteins ( < 20,000) as assessed by SDS-PAGE. Lipid A-associated
proteins have been observed to stimulate lymphocytes and macrophages
isolated from LPS-hyporesponsive murine strain C3H/HeJ. Removal of these
low molecular weight proteins from LPS preparations has been shown to
render LPS preparations inactive in stimulation of cellular responses from
C3H/HeJ cells. However, it has generally been observed that phenol-extracted
LPS is free of these contaminating proteins while butanol-extracted LPS
preparations are not. More importantly, the effect of these contaminating
proteins on LPS stimulation of normal LPS-responsive murine cells has been
shown to be relatively minor when comparing stimulation by butanol versus
phenol-extracted LPS preparations(40,74). Although the effect of lipid A-
associated protein on human monocyte secretory function remains to be
established, protein contaminants are undoubtedly associated with LPS and
may contribute to solubility and diffusion characteristics at disease sites.
Additional work is required to assess these possibilities.
In the present study, interferon did not increase the sensitivity of
monocytes to LPS since interferon effects were greater with high doses of LPS
but little to no potentiation was observed with low doses of LPS. This finding
is in conflict with several reports demonstrating an increased sensitivity of
mononuclear phagocytes to a variety of stimuli following IFN-/ treatment
(22,47). However, it must be stressed that our experimental design utilized
cotreatment conditions rather than the pretreatment protocols used previ-
ously. This may partially account for these differences.
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The mechanism by which IFN-/ can potentiate LPS stimulation is
unknown. The existence of IFN- receptors on the surface of the monocyte
has been demonstrated (6,13) and studies by Hamilton et al. (21) and Somers
et al. (64) have shown increased levels of intracellular Ca++ and protein
kinase C activity in murine monocytes following treatment with interferon.
These findings have recently been confirmed in experiments by Celada and
Schreiber (7). This evidence suggests that IFN-/acts on human monocytes
through a receptor mediated event which can elicit intracellular changes
consistent with cell activation. However, the selective potentiation of
Bacteroides over Salmonella LPS by IFN-, cannot be explained by the
mechanistic effects of interferon described to date. Further complicating the
issue is the lack of evidence concerning the exact mechanisms by which LPS
effects monocyte function. Clearly, more research is needed in these areas.
According to our results, we propose the following role for LPS in
activating monocytes in the established adult periodontitis lesion or any
lesion were chronic inflammatory and bacterial components are found. Once
recruited, mononuclear phagocytes are stimulated by LPS released from the
subgingival microflora, comprised in large part of Bacteroides species. This
results in the release of PGE2 and other soluble factors such as interleukin 1.
The LPS stimulated monocytes also stimulate the release of IFN-, from T
lymphocytes. IFN-/can then act in conjunction with LPS resulting in even
higher levels of PGE2 and/or IL-1 release from macrophages. LPS from
Bacteroides species are capable of a greater pathogenic potential for two
reasons" 1) IFN- potentiates the effect of Bacteroides LPS on monocyte
secretion of PGE2 and 2) lower concentrations of Bacteroides LPS would be
capable of eliciting release of PGE2 comparable to a higher dose of LPS without
interferon.
45
In summary, this study provides additional evidence supporting the
relatively weak endotoxic activity of LPS extracted from Bacteroides species
when compared to Salmonella. However, these results have also
demonstrated the capacity of IFN- to potentiate Bacteroides LPS stimulated
release of PGE2. This suggests a potential mechanism by which an otherwise
weak LPS can stimulate the release of significant levels of PGE2 in disease sites
where inflammatory and immune processes are activated, as with adult
periodontitis.
CHAPTER 4
Altered LPS-responsiveness in periodontitis patients, as measured by
monocyte release of PGE2 and IL-I.
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ABSTRACT
Lipopolysaccharide-responsiveness in human subjects was assessed
through the examination of LPS-stimulated PGE2 and IL-I[ release from
counterflow isolated monocytes from patients with varying levels of
periodontal destruction. This was performed in order to investigate a possible
relationship between LPS-mediated secretory responses in monocytes and
susceptability to periodontal destruction in humans. Subjects were chosen
based on apparent resistance or susceptibility to disease as measured by little
or no periodontal destruction versus generalized severe destruction,
respectively. Because IFN-/can influence LPS stimulated responses, the effect
of IFN-/on the LPS stimulated release of PGE2 and IL-11 was also assessed.
Peripheral blood monocytes were separated by counterflow centrifugation and
cultured (106/ml/well) with control medium or medium containing LPS
from Bacteroides gingivalis, B. intermedius, Actinobacillus actinomycetem-
comitans, or Salmonella typhimurium, with or without 10 Units/ml
recombinant IFN-% Media were exchanged at 24 and 48 hours and culture
supernatants assayed for both PGE2 and IL-I[ by RIA. Patients classified as
Susceptible to periodontitis, demonstrated 2-3 fold greater PGE2 release than
Resistant patients. This difference was observed with all LPS preparations
over both the 0-24 hour and 24-48 hour culture periods. IL-I release, how-
ever, was not significantly different between patient groups. IFN-, did not
affect the LPS stimulated release of PGE2 but significantly enhanced the
release of IL-I. The IFN-, effects were similar for both patient groups. These
findings indicate that LPS-stimulated PGE2 release from peripheral blood
monocytes may correlate with susceptibility to periodontitis in human
subjects.
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INTRODUCFION
Research conducted with C3H murine strains has determined a genetic
basis for differing host responses to bacterial lipopolysaccharide (LPS) (66). In
these studies, in vivo tests of LPS lethality have been used to describe LPS
susceptible (C3H/HeJ) and resistant (C3H/HeN) strains (74). Furthermore,
lethality has been correlated with the capacity of LPS to elicit PGE2 release
from peritoneal macrophages isolated from the same animals (74). Additional
work has established that in these animals the inherent susceptibility or
resistance to LPS is related to the expression of a specific LPS response gene,
located on chromosome 4 (75). Furthermore, immunological manifestations
in the expression of this genetic information are not limited to monocyte
function, as B lymphocyte blastogenesis can also be correlated with LPS
susceptibility in these murine strains.
Existence of a variable susceptibility to LPS in humans has not been
investigated to date, yet humans are afflicted with many diseases associated
with bacterial LPS. This includes diseases such as chronic adult periodontitis
which can lead to irreversible destruction of host tissues. Periodontitis is
associated with a predominantly gram negative bacterial flora located in the
periodontal pocket (32). LPS is a constituent of gram negative bacterial cell
walls and has been found in greatest quantity in the subgingival plaque layer
adjacent to the gingival tissues (14). Additional evidence has shown LPS to
penetrate intact sulcular epithelium (59), result in vascular leakage (51), and
correlate positively with clinical and histological signs of gingival
inflammation (61,62). Furthermore, LPS preparations isolated from many
suspected periodontal pathogens can elicit host responses including the
localized Schwartzman reaction (36,69), limulus lysate gelation, chick embryo
lethality (36), and bone resorption (24), as well as, specific cellular responses
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including the release of PGE2 (29) and IL-1 (2). Although there is a significant
body of evidence implicating LPS as a pathogenic substance in periodontitis,
little evidence exists demonstrating relative susceptibilities of human subjects
to such LPS preparations.
That human subjects express variable susceptibilities to periodontal
disease has been strongly suggested through longitudinal clinical studies of
tea plantation workers in Sri Lanka (33). According to the results of these
studies, a wide range of disease progression rates were observed which did not
correlate with levels of bacterial plaque accumulated on tooth surfaces.
Although variation in the composition of the bacterial flora undoubtedly
contributes to disease progression, it would be highly speculative to attribute
differences in progression solely to the variability in bacterial flora.
Alternatively, the variation in susceptibility to periodontitis could be partially
related to immune responses which are genetically determined. Little
research has been conducted to define such a process in humans, however,
the characteristics of adult periodontitis lends itself to studies concerning LPS-
responsiveness of human cells.
Therefore, the present study sought to assess the LPS-responsiveness of
subjects classified as Susceptible or Resistant to periodontitis. LPS stimulated
release of PGE2 and IL-I from peripheral blood monocytes served as the
measure of LPS-responsiveness. Furthermore, because gamma interferon
(IFN-/) has been shown to potentiate these LPS responses in humans (2,42)
and correct some aspects of the defective LPS response in C3H/HeJ mice (73),
the capacity of IFN-/ to modulate PGE2 and IL-I release was also examined
in these patients.
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METHODS AND MATERIALS
Patient Selection" Patients in good general health (free of any systemic
diseases), with a minimum of 20 teeth, were asked to participate in the study
if they fulfilled the selection criteria as depicted in Table 1. Seven Susceptible
and six Resistant patients were identified. All patients were free of non-
steroidal anti-inflammatory drug use for at least seven days prior to blood
donation. A bleeding on probing measurement was performed immediately
after blood drawing. This was used to assess whether a relationship could be
observed between periodontal inflammation and LPS-induced monocyte
secretory responses.
TABLE 1. PATIENT SELECTION CRITERIA
CRITERIA
Age
Mean Interproximal
Pocket Depth
Radiographic Bone Loss
Plaque Index
SUSCEPTIBLE
30-60 yrs
>5ram
>4O%
>1
RESISTANT
30-60 yrs
< 3.5 mm
no pockets > 5 mm
< 10%
>1
Cell Separation" Monocytes were separated from citrated whole
venous blood by ficoll-Hypaque sedimentation (400 x g x 35 min.) at 10oc.
The mononuclear leukocyte rich fractions were collected, diluted and washed
two times in Ca++ and Mg+/ free, phosphate buffered saline (PBS) (125 x g x 15
min.) at 10oc. The cells were then counted electronically (Coulter Electronics)
and monocyte enrichment achieved by counterflow centrifugation (Beckman
Instruments). Autologous plasma was added (final concentration of 1%) and
monocytes sedimented (125 x g x 15 min.) and resuspended in MCDB 104 (37)
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medium supplemented with 1% defined heat inactivated fetal calf serum
(Hyclone), 100 U/ml penicillin and 100 mcg/ml streptomycin. Cells were
counted and plated in plastic (Falcon Plastics) 16mm wells (1 x 106 cells/ml per
well). At 2 hours the cells were washed two times in medium to remove any
non-adherent cells. Cultures were incubated at 37oc in an H20 saturated 5%
CO2 atmosphere. Cell viability was routinely confirmed by trypan blue
exclusion. Treatments consisted of the following: LPS (10 ug/ml) or control
medium, with and without IFN- (10 Units/ml). Media were exchanged at 24
and 48 hours and the supernatants assayed for PGE2 and IL-I[ content.
LPS and IFN-y Preparations LPS was obtained from the following
bacterial strains: Salmonella typhimurium (Difco Laboratories), Bacteroides
gingivalis, Bacteroides intermedius and Actinobacillus actinomycetem-
comitans (kindly provided by Dr. Stan Holt, University of Texas Health
Center at San Antonio). All LPS preparations were extracted by the hot phe-
nol-water method of Westphal and Jann (76). Salmonella, B. intermedius,
and B. gingivalis LPS preparations were found to contain 5.1%, 6.9%, 11.9%
protein, respectively, as measured by Lowry assay (35). Protein was un-
detectable in the A.a. LPS preparation. Recombinant IFN- was purchased
from AMGEN Biochemicals with a specific activity of 1.6 x 107 Units/mg
protein calibrated against NIH IFN- standard GG-23-901-530.
Assay .for PGE2" Levels of PGE2 in the culture supernatants were
assayed by radioimmunoassay using absorption to dextran-coated charcoal.
Anti-PGE2 antibody and 3H-PGE2 were purchased from Seragen and New
England Nuclear, respectively. The anti-PGE2 antibody demonstrates 100%
cross-reactivity with PGE, however, other investigations in this laboratory
have demonstrated that the E series prostaglandin released from human
counterflow isolated monocytes consists of >97% PGE2 when assayed by gas
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chromatography-mass spectrometry (manuscript submitted). The PGE2
levels in culture supernatants were extrapolated from PGE2 standard binding
utilizing logit-log transformation.
Assay for Interleukin 1" Levels of IL-1[ in the culture supernatants
were assayed by radioimmunoassay purchased from Cistron. According to
recent evidence, IL-1[ represents approximately 90% of the total IL-1 released
from monocytes (46), with IL-la being 10%. The anti-IL-l[ antibody does not
cross-react with IL-10, IL-2, tumor necrosis factor, or IFN-/ (Cistron technical
bulletin). The IL-I[ levels in culture supernatants were extrapolated from IL-
1[ standard binding utilizing logit-log transformation.
Data Analysis" Data are depicted in Tables 2-5 as ng/ml of PGE2 or IL-
1[ in culture supernatants. Overall differences between Resistant and
Susceptible patients and interactions between variables were tested by three-
way ANOVA using STATUS (Resistant or Susceptible), LPS( A.a., B.
intermedius, B. gingivalis, Salmonella and none) and IFN (yes or no) as
independent grouping-variables and PGE2 or IL-I[ as dependent variables.
Differences between Susceptible and Resistant patients for each individual
treatment were tested by one-way ANOVA as noted in Table legends.
RESULTS
Patient data" The average age for patients in the Susceptible and
Resistant groups was 42.3 and 37.3 respectively. The mean interproximal
pocket depth was 5.1 and 2.7 mm for Susceptible and Resistant patients,
respectively.
LPS stimulated PGE2 release" Tables 2 and 3 demonstrate the data for
PGE2 release during the 0-24 and 24-48 hour intervals. During the first 24
hour interval, the difference between Resistant and Susceptible patients in
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LPS stimulation of PGE2 release was statistically significant at the p < .001
level, when analyzed by 3-way ANOVA. LPS also resulted in significant
effects at the p < .001 level. However, the effect of IFN-/ was not significant.
Furthermore, no interaction between variables was detected by this analysis.
One-way ANOVA was used to analyze differences between patient groups for
each individual LPS preparation, with or without IFN-/. As can be seen in
Table 2, the differences between Resistant and Susceptible were significant (p
< .05) with Salmonella and B. intermedius LPS (without IFN-, ), and
Salmonella, A. a., and B. intermedius (with IFN-/). In general, monocytes
from the Susceptible patients released approximately 2-fold greater PGE2 with
all LPS preparations tested.
During the 24-48 hour interval, the overall amounts of PGE2 released
were less than that observed during the initial 24 hour interval. However,
when examining the difference between Susceptible and Resistant patients, a
situation similar to the 0-24 hour interval was observed. As shown in Table
3, Susceptible patients released significantly (p < .001, by 3-way ANOVA)
greater PGE2 than Resistant patients. Using one-way ANOVA, significant (p
< .05) differences were noted for Salmonella LPS without IFN- and B.
intermedius with IFN-/. Susceptible and Resistant patients differed in PGE2
release by 3-fold during the second time interval. Again, interferon had no
significant effect as assessed by 3-way ANOVA.
LPS stimulated IL-I release" Data in Tables 4 and 5 represent IL-I
release from monocytes of Resistant and Susceptible patients during the first
(0-24 hour) and second (24-48 hour) time intervals. During the 0-24 hour
interval, the levels of IL-I were observed to be greater than the amounts of
PGE2 (Table 2) in the same monocyte culture media samples. More
+1
+1
+1
/1
+1
+1
+1
/1
+1
+1
+1
+1
+1
+1
+1
+1
+1
+1
+1
+1
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+1
+1
+1
+1
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importantly, however, no significant difference was observed between patient
groups with respect to LPS stimulated release of IL-113. The only significant
effect found by 3-way ANOVA was that of IFN-, (p < .05) and LPS (p < .001).
Interferon treatment resulted in approximately 30% greater release of IL-113
from monocytes stimulated with all LPS preparations except Salmonella.
IL-113 release decreased approximately 10 fold during the 24-48 hour
interval (Table 5). Again, interferon and LPS had significant effects both at the
p < .001 level; while no significant difference was found between Susceptible
and Resistant patients.
DISCUSSION
The present study has partially characterized certain LPS-elicited
secretory responses for monocytes isolated from patients with widely
disparate levels of periodontal destruction. Although PGE2 and IL-1[3 may be
important mediators in the pathogenesis of periodontitis, the primary goal of
this investigation was the examination of LPS-responsiveness of monocytes
and the relationship of those responses to disease severity in patients. A RIA
was used to quantify IL-1[3 so that chemical levels of IL-1[3 rather than biologic
activity was measured. Most previous investigations have measured IL-1
activity via the T lymphocyte blastogenesis bioassay. However, recent
evidence indicates that IL-1 activity is influenced by the presence of IL-1
inhibitor (1,15,31) which can be released from activated monocytes (1). The
RIA, which uses polyclonal anti-IL-l[3, would be less likely affected by an
inhibitor of biologic activity. To our knowledge, the only disadvantage with
the IL-113 RIA is that levels of IL-10 are not quantified. However, it has been
reported that IL-113 accounts for greater than 90% of the IL-1 released from LPS
treated monocytes (46).
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The patient selection criteria were intended to delineate subjects
representative of the extreme ends of the periodontitis spectrum while
demonstrating similar levels of plaque accumulation. Although these
patients were not representative of the average patient with adult
periodontitis, it was believed that these patients would offer the greatest
likelihood of expressing altered immune responses. Another requirement
for patient selection was that they be at least 30 years of age. It was felt that
this was the earliest age when differences in LPS-responsiveness would be
expressed by generalized periodontal status. Patients within the Susceptible
group were diagnosed as having generalized severe adult periodontitis,
whereas, the Resistant group represented patients with mild to moderate
gingivitis. According to our hypothesis, the LPS-elicited secretion of PGE2
and IL-1[ should be an inherent response unaffected by the stage of
periodontal treatment at blood donation. Therefore, patients in the
Susceptible group were chosen during various stages of periodontal therapy
ranging from recently diagnosed but not treated, to patients under
maintenance care. As an additional control for the influence of localized
periodontal inflammation on peripheral blood monocyte function, bleeding
on probing measurements were carried out at the time of blood donation.
Analyses of bleeding on probing showed no correlation with monocyte LPS-
responses.
LPS-responsiveness was assessed using LPS preparations isolated from
three suspected periodontal pathogens and Salmonella typhimurium.
Because the structure and biologic activity of Salmonella LPS have been well
characterized (16), this was chosen as a standard LPS preparation for
comparative purposes. Furthermore, Salmonella typhimurium is not an oral
inhabitant and therefore would elicit LPS responses which were unrelated to
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previous exposure through periodontal diseases. We have previously
characterized the relative potencies of the LPS preparations derived from the
suspected periodontal pathogens A. a., B. intermedius, and B. gingivalis All
were shown to be less potent than Salmonella (manuscript submitted).
However, in a separate study, the addition of 10 Units/ml recombinant IFN-
was shown to preferentially increase the LPS-response of Bacteroides LPS.
Therefore, the observed differences between LPS responses of Salmonella
and Bacteroides were greatly diminished by the addition of IFN-,. In the
present study, no significant differences in IFN-/effects on LPS-stimulated
monocyte responses were observed between Susceptible and Resistant patient
groups, regardless of the LPS preparation used.
The results from this study indicate that certain LPS-stimulated
responses in monocytes from patients classified as Susceptible differ from
those classified as Resistant. A two to three-fold greater release of PGE2 was
observed in monocytes of Susceptible patients, when compared to Resistant.
This was observed with all LPS preparations over both time intervals and was
not corrected by IFN-, treatment. In contrast, the levels of IL-1[ assayed in the
same culture supernatants were virtually identical between patient groups.
The fact that IL-1[ release did not differ significantly between patient groups
does not necessarily conflict with the genetic basis for LPS responses, as
observed in the C3H murine model. Recent experiments have demonstrated
that LPS from B. gingivalis and E. coli can stimulate IL-1 release from LPS-
hyporesponsive (C3H/HeJ) mice (23), although to a lesser extent than that
found with normal C3H/HeN mice. Therefore, IL-I[ release may not be as
sensitive a measure of LPS-responsiveness as the release of PGE2.
Furthermore, the variability in IL-I[ release between subjects (Table 4) is
much higher than that found with PGE2 release, thus further contributing to
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the difficulty of identifying small real differences, should they exist.
Additionally, the fact that PGE2 and IL-I[ release were not similarly effected
within the same patient group suggests that LPS stimulated release of PGE2
and IL-I[ are regulated by independent processes.
The relative differences between LPS preparations in the stimulation of
PGE2 release were consistent with a previous study (manuscript submitted)
which ranked LPS potencies as Salmonella > A. a. > B. intermedius > B.
gingivalis. This same ranking of potencies was also observed for IL-I[ release
in this study.
The present study also demonstrated that IFN-, alone, had no
significant effect on PGE2 and IL-I[ release from monocytes. However,
treatment of monocytes with interferon significantly enhanced LPS
stimulation of IL-1[ but not PGE2 release. This effect was equal for both
patient groups. Previous studies, in this laboratory and by others, have
demonstrated IFN-/enhancement of IL-1 (2) and PGE2 (42) release when
administered prior to LPS stimulation. However, the ability of IFN-, to
enhance LPS responses with simultaneous administration of both agents has
only recently been examined. Simultaneous, rather than sequential
treatment conditions were thought to more accurately reflect conditions at
sites of inflamed periodontal tissues. A study recently conducted in this
laboratory (manuscript submitted) demonstrated enhanced PGE2 release from
monocytes treated simultaneously with IFN-, and LPS from Bacteroides
species but not Salmonella. Interestingly, in the current study, a similar
process was observed with IL-I release. IFN-/ treatment resulted in
approximately a 30% increase in IL-I[ release with all LPS preparations except
that of Salmonella. PGE2 release also appeared to be enhanced by IFN-,
treatment during the 24-48 hour interval, however, these differences were
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not statistically significant. Throughout the duration of this study, the
activity of IFN-/was monitored by repeated experiments with the same donor
and through experiments using IFN- pretreatment conditions on LPS-
stimulated PGE2 release. No appreciable loss of IFN-/activity was observed.
That IFN-, did not significantly enhance PGE2 release in the present study,
may be partially explained by the unusual criteria used for patient selection,
since previous studies have utilized cells isolated from random normal
donors without regard to periodontal status.
It has recently been suggested that the release of PGE2 and IL-1 are not
independent events and are actually interrelated. In a recent paper by
Kunkel et al. (28), IL-1 was shown to stimulate PGE2 release, whereas,
exogenous PGE2 treatment resulted in decreased IL-1 release. Furthermore,
inhibition of PGE2 release by indomethicin resulted in elevated release of IL-
1. Therefore, elevated PGE2 levels should result in decreased IL-1 release.
According to the results of this study, Susceptible patients released
significantly greater (2-fold) levels of PGE2 without any pronounced effect on
IL-I release. The cells used in the present study were human peripheral
blood monocytes as opposed to the peritoneal macrophages used by Kunkel et
al., which may account for the discrepancy in findings. Another possibility is
that the RIA used in this study measured specific levels of IL-I and not IL-1
biologic activity, as in previous reports.
Although the periodontal .condition of a patient can be influenced by
many factors, of primary importance is the amount and specific bacterial
composition of plaque. The predisposition of an individual for periodontal
breakdown can only be expressed the presence of bacterial plaque. The results
of the present study suggest that in addition to bacterial factors, host factors
can influence cellular responses to a significant extent. Within the context of
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periodontitis susceptibility, the following considerations become important.
An overall increase in gram negative organisms within subgingival plaque
could offer a greater threat to periodontal health via increased levels of LPS.
However, because the potency of LPS varies with the bacterial source, some
plaques may pose a greater threat to health depending upon bacterial
composition. Therefore, generalized and localized periodontal destruction
could be influenced by the combined effects of the amount and specific
bacterial composition of plaque as well as the host response to the LPS
released by the plaque organisms. The 2 to 3-fold increased release of PGE2
demonstrated from the Susceptible patients examined in this study could
result in an overall increased inflammatory and depressed immune response
locally, thereby increasing the risk for periodontal destruction.
In summary, the present study consists of a preliminary investigation
of the LPS-responsiveness of patients classified as Susceptible or Resistant to
periodontitis. LPS-responsiveness was measured by monocyte release of PGE2
and IL-1[. LPS stimulation of monocytes from patients classified as
Susceptible released 2-3 fold greater PGE2 than Resistant patients. In contrast,
IL-1]3 release was similar for both patient groups. Simultaneous treatment of
monocytes with IFN-7 was shown to enhance the amount of IL-1] released
from LPS stimulated monocytes but not PGE2. Therefore, the altered PGE2
release between patient groups was not minimized by IFN-7.
DISCUSSION
The objectives of this research project were three-fold: 1) determine the
relative capacity of LPS preparations from various suspected periodontal
pathogens to elicit PGE2 and/or IL-I[ release from human monocytes, 2)
characterize the effects of IFN-/on these LPS responses, and 3) determine if
the capacity of monocytes to respond to LPS is related to susceptibility to
periodontal destruction in human subjects.
The present findings indicate that LPS from B. intermedius, B.
gingivalis, Actinobacillus actinomycetemcomitans, and Wolinella recta can
stimulate the release of PGE2 and IL-I[ from human monocytes. However,
the relative potencies vary between species, with all periodontal species except
Wolinella being less potent than Salmonella typhimurium. The relative
weakness of LPS from suspected periodontal pathogens (A.a., B. intermedius,
and B. gingivalis) was consistent with other investigations (26,36,41). Of
interest was the finding that Wolinella LPS potency was equal to or greater
than Salmonella and did not diminish over time as did all other
preparations. However, comparison of Wolinella LPS potency is limited
since it was prepared by a method different from all other LPS preparations.
Furthermore, little information exists with respect to its chemical
composition. Thus, these studies indicated relative potencies of the LPS
preparations as follows: Wolinella > Salmonella > A. a. > B. intermedius >
B. gingivalis. This ranking was found to be consistent throughout all
experiments with the exception of Wolinella which was not used in other
experiments, due to a limited supply. Although IL-I release was not
reported (due to the high cost of the RIA) for the comparative experiments
(chapter 1), a limited analysis of dose responses with all LPS preparations,
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except Wolinella was performed. Results demonstrated the same relative
potencies as were found with PGE2 release. Furthermore, the IL-I results
from the clinical study demonstrated similar relative potencies.
Differences in chemical composition between LPS preparations and
their influence on LPS-stimulation of monocyte secretory responses were
discussed in Chapters 1 and 3. Additionally, the importance of protein
contaminants in monocyte activation processes were also considered,
however, protein contaminants have not been tested for their ability to
influence human monocyte secretory responses. Although it is important to
minimize natural protein contaminants within LPS preparations, specific
cellular responses in vivo are likely to involve LPS which contains protein
contaminants. Therefore, more research is needed on the effects of protein
contaminants.
When considering LPS pathogenic mechanisms relating to monocyte
secretory function, the potentiating effects of IFN-/ are clearly important.
Diseases which involve LPS-activation of monocytes in the presence of T
lymphocytes, are likely to result in elevated release of IFN-. This idea stems
from the finding that small percentages (10%) of monocytes in combination
with T lymphocytes and LPS, result in elevated IFN-, production (30). In
addition, separate studies in this laboratory have found that media from LPS-
treated monocytes can replace the need for intact monocytes in this process.
However, LPS alone or in combination with IL-I[ could not stimulate IFN-,
release from T lymphocytes.
The effects of IFN-, on LPS responses in monocytes were characterized
for both pretreatment and simultaneous treatment conditions. Interestingly,
the magnitude of IFN- effects was significantly influenced by treatment
conditions. A much greater effect was observed when IFN-, was used prior to
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LPS stimulation than simultaneously with LPS. This was found for PGE2
measured by both RIA and labeled metabolite release. It should be recalled
that only Salmonella LPS was used for this portion of the study.
It was believed that simultaneous exposure of monocytes to IFN-, and
LPS was more likely to represent conditions as they would occur in vivo,
particularly in chronic adult periodontitis. Therefore, a thorough
examination of the effect of IFN-, under simultaneous treatment conditions
was undertaken using LPS preparations from B. gingivalis, B. intermedius,
and Salmonella. A.a. was also tested but results are not presented here. Dose
responses were performed for.LPS preparations and IFN-/. Of primary interest
was the observation that IFN-, treatment resulted in up to 3-fold greater PGE2
release from monocytes treated with either Bacteroides LPS, while minimal
enhancement of the Salmonella LPS response was observed. The
significance of this finding was that an otherwise weak LPS preparation was
able to stimulate PGE2 release in amounts similar to that of Salmonella. This
finding may be important with respect to the pathogenicity of LPS in certain
periodontal diseases, since high numbers of Bacteroides species have been
well associated with chronic adult periodontitis (12). Furthermore, the weak
potency of Bacteroides LPS without the influence of IFN-/could lead to the
incorrect conclusion that LPS is primarily a weak virulence factor for
Bacteroides species.
The effect of IFN-/on LPS stimulated IL-I[ release was not investigated
during the initial experiments.because the IL-I RIA was unavailable.
However, Arenzana-Siesdedos et al. (2) presented convincing evidence that
preincubation with IFN- could not only enhance LPS-stimulated IL-1 release
but prolong the duration of time in which monocytes could respond to LPS.
This finding is consistent with the data presented here (chapter 2) concerning
PGE2 release. Furthermore, results from the clinical study have shown a
statistically significant enhancement of IL-I[ release with IFN-/and LPS
cotreatment. Therefore, IFN-, appears to enhance both LPS-stimulated PGE2
and IL-1 release from human monocytes under both simultaneous and
pretreatment conditions.
The effect of IFN-/was not equal for all LPS preparations examined. In
fact, simultaneous treatment with Salmonella LPS and IFN-, did not
significantly effect PGE2 release. With respect to IL-I[ release in the clinical
study, IFN- also failed to effect Salmonella LPS while enhancing all other
LPS preparations. However, it would be incorrect to conclude that
Salmonella LPS responses are not modulated by IFN-/. The IFN-/ dose
response data presented in chapter 3 indicated that higher doses of IFN- can
enhance Salmonella LPS-stimulated PGE2 release. In addition, Arenzana-
Siesdedos et al. (2) utilizing LPS from Salmonella, demonstrated that
pretreatment with IFN- greatly enhanced Salmonella LPS-stimulated IL-1
release. In the experiments presented in chapter 3, data were not reported
concerning IFN-/cotreatment effects on Salmonella LPS-stimulated IL-I[
release. However, supernatants from the experiments which tested larger
doses of IFN-, with Salmonella LPS (10 ug/ml) have recently been assayed for
IL-I[. IFN-/ (100 and 1000 Units/ml) was found to markedly increase
Salmonella LPS-stimulated IL-I release. The fact that Salmonella LPS was
much more potent in the stimulation of PGE2 and IL-I[ release probably
accounts for the difficulty in observing a substantial effect of IFN-. As stated
in chapter 3, monocytes may be primed for a maximal stimulatory capacity to
LPS when exposed to IFN-/, regardless of the LPS preparation. When all the
data are considered, a conclusion can be reached that IFN-, consistently acts to
enhance the potency of LPS to stimulate PGE2 and IL-I release from human
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monocytes. This effect occurs under simultaneous and pretreatment
conditions; however, the magnitude of the effect varies with the bacterial
source of the LPS.
The examination of LPS-responsiveness in clinical patients, classified
as Susceptible or Resistant, produced some of the most interesting findings
from this research project. The dramatic elevation in LPS-stimulated PGE2
release in the Susceptible group could have profound effects on the immune
and inflammatory responses in vivo. Elevated PGE2 levels could act to
suppress the immune response, elevate the inflammatory response, and
cause greater bone resorption.
The hypothesis that patients may differ in the ability to respond to LPS
is attractive to periodontology for a number of reasons. In periodontitis, only
a thin layer of stratified squamous epithelium separates large quantities of
bacterial LPS from cells involved in the regulation of immune and
inflammatory responses. Furthermore, the fact that LPS can readily pass
through sulcular epithelium and that antibodies to various LPS preparations
can be detected in the peripheral blood of periodontitis patients, suggests that
cells found within the connective tissue adjacent to the sulcular epithelium
are exposed to LPS. The degree to which gingival cells are exposed to LPS is,
as yet, poorly characterized. However, topical application of LPS to tooth
surfaces in periodontally healthy dogs is sufficient to elicit alterations in
vascular permeability in the adjacent gingival tissues (51).
The following proposed model can partially account for the variable
susceptibility observed with chronic periodontitis. The response to LPS is
variable between individuals such that a LPS-response characteristic of a
resistant individual would be associated with the development of gingivitis
or mild periodontitis whereas a response consistent with a susceptible
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individual would be more likely to develop severe periodontitis. The overall
amount of LPS and the specific bacteria from which LPS is produced would
also play a major role in the severity and localization of periodontal
destruction. For example, a person classified as susceptible who practices
meticulous oral hygiene except in certain areas would likely only have severe
periodontal destruction at those sites which consistently retain plaque.
Therefore, individuals of equal age with localized or generalized severe
periodontitis would be expected to demonstrate equal LPS-responsiveness.
The localization of periodontal breakdown would correlate best with plaque
accumulation whereas LPS-responsiveness would correlate with the severity
of destruction. Also, depending on the types and numbers of specific
organisms within subgingival plaque, there could be a greater or lesser
potential for destruction. Therefore, the pathogenic potential of a subgingival
plaque will depend on the summed LPS challenge of all microorganisms
present. Generalized and localized periodontal destruction could be
influenced by the combined effects of the amount and specific bacterial
composition of plaque and the type of response to the LPS released by the
plaque organisms. This point is important because it demonstrates how the
specific and non-specific plaque hypotheses are consistent with the proposed
model.
In summary, the previously described findings demonstrate a
relationship between LPS-mediated responses in monocytes and susceptibility
to periodontal destruction in human subjects. Although monocytes may
participate in the pathogenesis of periodontitis, the response to LPS
demonstrated by these cells is proposed to reflect overall LPS-responsiveness.
Indeed, it is likely that other cell types are involved in periodontal
destruction. However, it is proposed that the monocyte response to LPS
reflects the potential for these other cells to be directly involved with LPS-
initiated periodontal destruction. Future work should help to clarify these
concepts.
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